Clinical Relevance of Pharmacogenetics in Serotonin Syndrome
Joint Authors
Pandya, Dehuti
Tran, My
Verduzco-Gutierrez, Monica
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-10-08
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Serotonin syndrome is a predictable life-threatening condition that is caused by serotonergic stimulation of the central and peripheral nervous systems.
A patient’s genetic profile can amplify exposure risk as many serotonergic drugs are metabolized by CYP450 enzymes, and these enzymes may be altered in functionality.
We report a case of an elderly man who presented with serotonin syndrome after a dose change in valproic acid 5 weeks prior.
His medication list consisted of low-dose serotonergic agents, which is unusual as most cases of serotonin syndrome involve higher doses.
A review of his pharmacogenetic profile is presented to retrospectively evaluate the additive risk for serotonin syndrome and implications on resuming serotonergic agents.
American Psychological Association (APA)
Pandya, Dehuti& Tran, My& Verduzco-Gutierrez, Monica. 2020. Clinical Relevance of Pharmacogenetics in Serotonin Syndrome. Case Reports in Psychiatry،Vol. 2020, no. 2020, pp.1-7.
https://search.emarefa.net/detail/BIM-1150937
Modern Language Association (MLA)
Pandya, Dehuti…[et al.]. Clinical Relevance of Pharmacogenetics in Serotonin Syndrome. Case Reports in Psychiatry No. 2020 (2020), pp.1-7.
https://search.emarefa.net/detail/BIM-1150937
American Medical Association (AMA)
Pandya, Dehuti& Tran, My& Verduzco-Gutierrez, Monica. Clinical Relevance of Pharmacogenetics in Serotonin Syndrome. Case Reports in Psychiatry. 2020. Vol. 2020, no. 2020, pp.1-7.
https://search.emarefa.net/detail/BIM-1150937
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1150937